Veru also evaluates antagonist three-month depot formulation in Phase 2 dose-finding clinical study to treat hormone-sensitive advanced prostate cancer.

Source: https://seekingalpha.com/article/4582456-veru-inc-q1-revenues-fall-short-and-uncertainty-looms-making-it-risky?source=feed_all_articles

Veru plans to continue development of the oral drug, sabizabulin, in late-stage studies with high-risk hospitalized influenza patients and COVID-19 patients.

Source: https://1010wcsi.com/fox-news/veru-to-proceed-with-late-stage-study-of-covid-pill-despite-fda-snub/?utm_source=rss&utm_medium=rss&utm_campaign=veru-to-proceed-with-late-stage-study-of-covid-pill-despite-fda-snub

Without that EUA, Veru will be delayed in getting its Covid-related treatment to market.

Source: https://investorplace.com/2023/03/why-is-veru-veru-stock-down-37-today/